The FDA may soon review what could become the first approved psilocybin-based therapy for treatment-resistant depression (TRD). Compass Pathways' COMP360, a synthetic psilocybin capsule, is expected to complete its FDA submission by the end of 2026, with a potential launch in 2027 pending regulatory approval and DEA rescheduling.
Why does this matter?
• Treatment-resistant depression remains a significant unmet clinical need.
• Phase 3 data demonstrated improvements in depressive symptoms, with responses lasting up to one year in some patients.
• Unlike existing therapies such as Spravato®, which require ongoing maintenance dosing, COMP360 may offer benefits with significantly fewer administrations.
• The therapy has received FDA Breakthrough Therapy designation, highlighting its potential importance in addressing serious mental illness.
As the behavioral health landscape continues to evolve, employers, health plans, and pharmacy benefit stakeholders should closely monitor emerging therapies that may reshape treatment options, access considerations, and future pharmacy spend.
At ProAct, we remain committed to tracking pipeline developments and helping our clients understand the clinical and financial implications of innovative therapies.
